ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0531

The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records

Sunali Goonesekera1, Ankit Bansal1, Swarali Tadwalkar2 and Alison Isherwood3, 1Decision Resources Group, Part of Clarivate, Boston, MA, 2Decision Resources Group, part of Clarivate, Bangolore, India, 3Decision Resources Group, part of Clarivate, London, United Kingdom

Meeting: ACR Convergence 2020

Keywords: dermatomyositis, Epidemiology, giant cell arteritis, race/ethnicity, Scleroderma

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Epidemiological studies suggest differences in the prevalence and disease severity of certain autoimmune diseases by race and ethnicity. In this study, we evaluate the distribution of three rare connective-tissue diseases i.e., systemic sclerosis (SSc), dermatomyositis/polymyositis (DM/PM), and giant cell arteritis (GCA), in different racial/ethnic groups in the United States using data from electronic health records (EHR).

Methods:

We restricted the study population to patients aged 20 or older, who had submitted at least two insurance claims in 2018 (Real World Data. Decision Resources Group, 2020), and had no missing information in their EHR regarding age, gender, and race/ethnicity. We categorized the patients with respect to age (≤65 versus 65+ for SSC and DM/PM; 50-65 versus 65+ for GCA) and race/ethnicity (non-Hispanic White (NHW), non-Hispanic Black (NHB), Hispanic, and non-Hispanic Asian (NHA)). To be considered a case, a patient was required to have at least two diagnoses recorded for each autoimmune disease in 2018. For each racial/ethnic category, we estimated the age-group-specific diagnosed prevalence of SSc, DM/PM, and GCA, and calculated the diagnosed prevalence ratios for NHBs, Hispanics, and NHAs using NHWs as the referent population.

Results: In persons aged ≤65, we observed a significantly increased risk of SSc in NHBs (RR=1.10; 95% CI = 1.04-1.16) and Hispanics (RR = 1.26, 95% CI = 1.19-1.35) as compared to the NHW population, but not in NHAs (RR = 0.89, 95% CI = 0.74-1.07). Interestingly, the pattern was reversed in NHBs aged 65+, with a significantly lower diagnosed prevalence of SSc (RR = 0.48; 95% CI = 0.44-0.52) as compared to NHWs. We also observed a reduced risk of SSc in Hispanics (RR=0.92, 95% CI = 0.86-0.99) and in NHAs (RR = 0.71; 95% CI = 0.58-0.87) in the older age-group. The risk of DM/PM in both age-groups was elevated in NHBs (ages ≤65: RR = 1.51, 95% CI = 1.40-1.63; ages 65+: RR = 1.15, 95% CI = 1.03-1.29) and Hispanics (ages ≤65: RR = 1.34, 95% CI = 1.22-1.47; ages 65+ RR = 1.20, 95% CI = 1.06-1.35) as compared to NHWs, but not in NHAs (ages ≤65: RR = 0.83, 95% CI = 0.62-1.10; ages 65+: RR = 1.08, 95% CI = 0.79-1.48). We observed a significantly reduced risk of GCA in NHBs in both age groups (ages ≤65: RR = 0.83, 95% CI = 0.75-0.92; ages 65+: RR = 0.63, 95% CI = 0.56-0.71) as compared to NHWs, while no significant difference was observed in Hispanics (ages ≤65: RR = 1.10, 95% CI = 0.99-1.23; ages 65+: RR = 0.95, 95% CI = 0.86-1.05) and in NHAs (ages ≤65: RR = 0.91, 95% CI = 0.67-1.25; ages 65+: RR = 0.87, 95% CI = 0.67-1.14).

Conclusion: Our results concur with findings of other epidemiological studies that have observed a higher prevalence of SSc and DM/PM and a lower prevalence of GCA in certain ethnic groups as compared to NHWs. However, the lower prevalence of SSC observed in NHBs and Hispanics aged 65+ warrants further investigation, as it may indicate early mortality in these patients known to experience more severe disease.

Diagnosed prevalence of SSc, DM/PM, and GCA by race and ethnicity

Risk ratios (95% confidence intervals) for SSc, DM/PM, and GCA _ minority ethnicities versus non-HIspanic Whites


Disclosure: S. Goonesekera, None; A. Bansal, None; S. Tadwalkar, None; A. Isherwood, None.

To cite this abstract in AMA style:

Goonesekera S, Bansal A, Tadwalkar S, Isherwood A. The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-prevalence-of-systemic-sclerosis-dermatomyositis-polymyositis-and-giant-cell-arteritis-in-the-united-states-by-race-and-ethnicity-an-analysis-using-electronic-health-records/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-systemic-sclerosis-dermatomyositis-polymyositis-and-giant-cell-arteritis-in-the-united-states-by-race-and-ethnicity-an-analysis-using-electronic-health-records/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology